智通财经APP获悉，据报道，辉瑞(PFE.US)即将以73亿美元收购减肥药初创公司Metsera(MTSR.US)，此 举旨在其备受关注的减肥药项目近期受挫后强化产品线布局。据知情人士透露，该交易最早可能于周一 正式宣布。辉瑞将以每股47.50美元现金收购Metsera，若达成特定业绩里程碑，还将额外支付每股22.50 美元，这一报价较Metsera上周五33.32美元的收盘价显著溢价。截至非工作时间，双方暂未对此置评。 作为新一代减肥药物领域的潜力企业之一，Metsera正参与争夺规模达数十亿美元的减肥药市场。收购 完成后，辉瑞将获得Metsera的减肥针剂MET-233i——在早期小型试验中，该药物帮助患者在36天内减 重最多达8.4%。 值得关注的是，与诺和诺德(NVO.US)、礼来(LLY.US)等市场龙头的现有产品相比，MET-233i可能实现 更低频次给药，使患者从每周注射一次减少至每月一次，可能与现有疗法形成差异。 据悉，辉瑞计划今年完成两至三笔总规模达150亿美元的交易以补充产品线，其自有减肥药业务此前被 视为进军该市场的核心突破口，但其减肥药丸项目的失败加大了首席执行官阿尔伯特·布尔拉的压力 ...

Pfizer is making a bold move in the pharmaceutical world by closing in on a $7.3 billion deal to acquire Metsera, a biotech firm focused on next-generation anti-obesity drugs, news platform Financial Times reported on Monday. ...

Mergers and Acquisitions - Pfizer is nearing a potential $73 亿 (billion) 美元的收购，目标是肥胖症初创公司 Metsera [1]

Group 1 - Pfizer is nearing a potential acquisition of Metsera, a developer of anti-obesity drugs, valued at $7.3 billion [1] - The information regarding the acquisition was reported by the Financial Times, citing unidentified sources [1] Group 2 - The acquisition reflects Pfizer's strategic interest in expanding its portfolio in the anti-obesity drug market [1] - Metsera's development focus aligns with the growing demand for obesity treatments, indicating a significant market opportunity [1]

(Reuters) -Pfizer (PFE) said on Monday it would acquire weight-loss drug developer Metsera (MTSR) in a deal valued at up to $7.3 billion, including future payments, to secure its position in the lucrative obesity treatment market. The global obesity drug market, projected to reach $150 billion by early 2030s, has been booming over the last few years, driven by the success of highly effective GLP-1-targeting therapies from companies such as Novo Nordisk (NVO, NOVO-B.CO) and Eli Lilly (LLY) — both fiercely ...

Core Viewpoint - Pfizer is nearing a $7.3 billion acquisition of the weight-loss drug company Metsera, offering $47.5 per share in cash [1] Group 1 - Pfizer's acquisition price for Metsera is set at $47.5 per share in cash [1] - The total value of the acquisition is approximately $7.3 billion [1]

Group 1: Company Overview - Pfizer Inc. is a global pharmaceutical leader focusing on mRNA vaccines, oncology, immunology, and infectious diseases, with notable recognition for its COVID-19 vaccine collaboration with BioNTech [1][2] - The company is advancing its mRNA vaccine portfolio, recently announcing progress with its LP.8.1-adapted COMIRNATY 2025-2026 formula [1] Group 2: Vaccine Development - In September 2025, Pfizer reported positive Phase 3 topline data showing a fourfold increase in neutralizing antibodies in adults aged 65+ and high-risk adults aged 18–64, supporting FDA approval [2] - The adaptive vaccine targets emerging SARS-CoV-2 sublineages, reinforcing Pfizer's strategic direction to maintain vaccine efficacy amid changing pandemic conditions [2] Group 3: Oncology and Specialty Medicines - Pfizer is advancing oncology and specialty medicines, with combination therapy PADCEV plus KEYTRUDA showing improved survival rates in bladder cancer [3] - The company is also progressing with HYMPAVZI for hemophilia treatment, demonstrating its commitment to high-need therapeutic areas [3] Group 4: Research and Development Focus - Despite facing regulatory challenges and patent litigation over Paxlovid, Pfizer continues to invest in R&D and strategic partnerships [4] - The company's focus on adaptive mRNA technology, AI-driven development, and precision medicine highlights its leadership among biotech innovators [4]

Core Viewpoint - The article discusses the financial challenges faced by American households and suggests three bargain stocks that could be considered for investment, emphasizing the need for cost-effective investment strategies in a tight financial environment [1][2][3]. Group 1: Pfizer - Pfizer's stock has seen a 60% decline from its late-2021 high, primarily due to the waning demand for its COVID-19 vaccine and treatment, with projected revenue dropping from $100 billion in 2022 to $63 billion in 2023 [5][6]. - Despite current challenges, Pfizer has a robust pipeline with 18 phase 3 oncology drugs, including Elrexfio and Sigvotatug vedotin, which could generate over $1 billion in annual sales each by 2030 [7][8]. - The stock is currently priced at about 8 times next year's expected per-share earnings, with a forward-looking dividend yield of 7.1%, making it attractive for investors seeking regular cash flow [9]. Group 2: Uber Technologies - Uber Technologies is trading at over 30 times this year's projected per-share profit, but its growth potential is significant, driven by changing consumer preferences away from car ownership, particularly among younger generations [10][12]. - A Deloitte survey indicates that 44% of 18- to 34-year-olds are considering forgoing car ownership, which supports Uber's growth trajectory as this demographic matures [12][13]. - The company's ability to maintain its growth rate positions it well for future valuation increases, despite current pricing levels [13]. Group 3: Qualcomm - Qualcomm is positioned to benefit from the growing mobile AI market, which is expected to expand at an annualized rate of nearly 29% through 2033, as mobile devices increasingly handle AI tasks onboard [14][16]. - The company has made strides in the automotive sector, collaborating with BMW on an automated driving assistance system, enhancing its market presence [17]. - Qualcomm's stock is currently priced at only 14 times this year's anticipated per-share earnings, indicating potential for upside as the demand for affordable mobile AI processors increases [18].

Group 1 - Pfizer Inc. is recognized as one of the 12 Best Dividend Paying Stocks to buy currently [1] - The company reported a 10% year-over-year increase in revenue and a 30% rise in earnings per share for the second quarter [3] - Pfizer has a strong dividend history, having increased its dividends for 25 consecutive years, with a current quarterly dividend of $0.43 per share and a dividend yield of 7.16% as of September 19 [4] Group 2 - Pfizer is among the world's leading pharmaceutical companies, with significant resources dedicated to research and development [2] - The drug discovery and approval process is complex and time-consuming, with no guarantees despite substantial funding [2] - Management has raised the full-year 2025 adjusted diluted EPS guidance, indicating confidence in the company's strategic execution and shareholder returns [3]

Industry Overview - Healthcare stocks are currently at their lowest valuations in three decades, presenting potential investment opportunities for opportunistic investors [1] - The industry has faced significant challenges recently, but many healthcare stocks are available at reasonable valuations relative to their growth potential [1] Company Analysis: Pfizer - Pfizer is facing several patent cliffs, including the anticoagulant Eliquis, which will lose patent exclusivity by 2029, contributing to its poor market performance [4] - Despite recent challenges, Pfizer's revenue increased by 10% year over year to $14.7 billion in Q2, with adjusted earnings per share growing 30% to $0.78 [5] - The company has a promising pipeline, with new products like Abrysvo, a vaccine for respiratory syncytial virus, seeing a 155% revenue increase year over year to $143 million [6] - Pfizer has improved its pipeline through licensing deals and acquisitions, particularly in oncology, which is expected to yield excellent clinical results in the coming years [7] - Cost-cutting efforts are underway, with projected net savings of $4.5 billion by the end of the year and $7.2 billion by 2027, which will enhance profitability [8] Investment Consideration - The current market conditions make it a favorable time to invest in healthcare stocks, particularly Pfizer and Vertex Pharmaceuticals, as Pfizer's financial results and pipeline improvements position it well to navigate upcoming challenges [9]